Morningstar, Inc. - August 14, 2025
The More Investors Traded, the Less Their Average Dollar Made
Plus: After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly...
 Morning DigestAugust 14, 2025 Jeffrey Ptak And four other lessons from our annual ‘Mind the Gap’ study. 
ADVERTISEMENT  Editor's Picks   Morningstar experts on the growing opportunity in international stocks and whether bonds are attractive in today’s market. Jess Bebel  The dividend growth universe is changing. Here’s what that means for investors. Dan Lefkovitz  Interest rates, tax brackets, and Social Security payments all ride on independent oversight of US economic data. Hal Ratner  Investors should look beyond growth forecasts, study suggests. Larry Swedroe Investing Insights The IPO market is heating up. Rosie Bradbury With state-of-the-art AI solutions in a still-growing market, here’s what we think of Palantir’s stock. Mark Giarelli These ETFs are a one-stop shop for global diversification. Zachary Evens Tracking two index bond funds reveals how small differences can result in performance deviations during stress markets. Lan Anh Tran We think GE Aerospace stock is fairly valued. Nicolas Owens The fixed-income exchange-traded funds on this list earn Morningstar’s top rating. Tori Brovet New Stock Analyst Reports Gilead's (GILD) total product sales grew 2% in the second quarter, with flat non-GAAP EPS. Management raised product sales guidance by $100 million and earnings guidance by $0.20 at the midpoint for the full year. The US Food and Drug Administration approved Yeztugo for HIV prevention in June. Despite a 44% decline in sales of covid treatment Veklury in the second quarter due to fewer covid hospitalizations, as well as HIV pressure from Medicare reimbursement changes, the strength of the HIV business allowed management to raise its 2025 outlook. New Fund Analyst Reports American Funds Growth and Income series (GAIOX) sports a top management team that guides its distinctive objectives-based approach, which is built on robust multi-asset research. This standout series is a great choice for investors seeking capital appreciation and income. The series’ three portfolios are available as model portfolios, separate accounts, and mutual funds. The Tools You Need to Invest Like an Analyst Stay connected:
|
